Cargando…

Incretins in patients with rheumatoid arthritis

BACKGROUND: The precise mechanism linking systemic inflammation with insulin resistance (IR) in rheumatoid arthritis (RA) remains elusive. In the present study, we determined whether the incretin-insulin axis and incretin effect are disrupted in patients with RA and if they are related to the IR fou...

Descripción completa

Detalles Bibliográficos
Autores principales: Tejera-Segura, Beatriz, López-Mejías, Raquel, Domínguez-Luis, María Jesús, de Vera-González, Antonia M., González-Delgado, Alejandra, Ubilla, Begoña, Olmos, José M., Hernández, José L., González-Gay, Miguel A., Ferraz-Amaro, Iván
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645916/
https://www.ncbi.nlm.nih.gov/pubmed/29041949
http://dx.doi.org/10.1186/s13075-017-1431-9
_version_ 1783271981196509184
author Tejera-Segura, Beatriz
López-Mejías, Raquel
Domínguez-Luis, María Jesús
de Vera-González, Antonia M.
González-Delgado, Alejandra
Ubilla, Begoña
Olmos, José M.
Hernández, José L.
González-Gay, Miguel A.
Ferraz-Amaro, Iván
author_facet Tejera-Segura, Beatriz
López-Mejías, Raquel
Domínguez-Luis, María Jesús
de Vera-González, Antonia M.
González-Delgado, Alejandra
Ubilla, Begoña
Olmos, José M.
Hernández, José L.
González-Gay, Miguel A.
Ferraz-Amaro, Iván
author_sort Tejera-Segura, Beatriz
collection PubMed
description BACKGROUND: The precise mechanism linking systemic inflammation with insulin resistance (IR) in rheumatoid arthritis (RA) remains elusive. In the present study, we determined whether the incretin-insulin axis and incretin effect are disrupted in patients with RA and if they are related to the IR found in these patients. METHODS: We conducted a cross-sectional study that encompassed 361 subjects without diabetes, 151 patients with RA, and 210 sex-matched control subjects. Insulin, C-peptide, glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), dipeptidyl peptidase 4 (DPP-4) soluble form, and IR indexes by homeostatic model assessment (HOMA2) were assessed. A multivariable analysis adjusted for IR-related factors was performed. Additionally, ten patients and ten control subjects underwent a 566-kcal meal test so that we could further study the postprandial differences of these molecules between patients and control subjects. RESULTS: Insulin, C-peptide, and HOMA2-IR indexes were higher in patients than in control subjects. This was also the case for GLP-1 (0.49 ± 1.28 vs. 0.71 ± 0.22 ng/ml, p = 0.000) and GIP (0.37 ± 0.40 vs. 1.78 ± 0.51 ng/ml, p = 0.000). These differences remained significant after multivariable adjustment including glucocorticoid intake. Disease Activity Score in 28 joints with erythrocyte sedimentation rate (β coefficient 46, 95% CI 6–87, p = 0.026) and Clinical Disease Activity Index (β coefficient 7.74, 95% CI 1.29–14.20, p = 0.019) were associated with DPP-4 serum levels. GLP-1 positively correlated with β-cell function (HOMA2 of β-cell production calculated with C-peptide) in patients but not in control subjects (interaction p = 0.003). The meal test in patients with RA revealed a higher total and late response AUC for glucose response, a later maximal response of C-peptide, and a flatter curve in GIP response. CONCLUSIONS: The incretin-insulin axis, both during fasting and postprandial, is impaired in patients with RA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-017-1431-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5645916
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56459162017-10-26 Incretins in patients with rheumatoid arthritis Tejera-Segura, Beatriz López-Mejías, Raquel Domínguez-Luis, María Jesús de Vera-González, Antonia M. González-Delgado, Alejandra Ubilla, Begoña Olmos, José M. Hernández, José L. González-Gay, Miguel A. Ferraz-Amaro, Iván Arthritis Res Ther Research Article BACKGROUND: The precise mechanism linking systemic inflammation with insulin resistance (IR) in rheumatoid arthritis (RA) remains elusive. In the present study, we determined whether the incretin-insulin axis and incretin effect are disrupted in patients with RA and if they are related to the IR found in these patients. METHODS: We conducted a cross-sectional study that encompassed 361 subjects without diabetes, 151 patients with RA, and 210 sex-matched control subjects. Insulin, C-peptide, glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), dipeptidyl peptidase 4 (DPP-4) soluble form, and IR indexes by homeostatic model assessment (HOMA2) were assessed. A multivariable analysis adjusted for IR-related factors was performed. Additionally, ten patients and ten control subjects underwent a 566-kcal meal test so that we could further study the postprandial differences of these molecules between patients and control subjects. RESULTS: Insulin, C-peptide, and HOMA2-IR indexes were higher in patients than in control subjects. This was also the case for GLP-1 (0.49 ± 1.28 vs. 0.71 ± 0.22 ng/ml, p = 0.000) and GIP (0.37 ± 0.40 vs. 1.78 ± 0.51 ng/ml, p = 0.000). These differences remained significant after multivariable adjustment including glucocorticoid intake. Disease Activity Score in 28 joints with erythrocyte sedimentation rate (β coefficient 46, 95% CI 6–87, p = 0.026) and Clinical Disease Activity Index (β coefficient 7.74, 95% CI 1.29–14.20, p = 0.019) were associated with DPP-4 serum levels. GLP-1 positively correlated with β-cell function (HOMA2 of β-cell production calculated with C-peptide) in patients but not in control subjects (interaction p = 0.003). The meal test in patients with RA revealed a higher total and late response AUC for glucose response, a later maximal response of C-peptide, and a flatter curve in GIP response. CONCLUSIONS: The incretin-insulin axis, both during fasting and postprandial, is impaired in patients with RA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-017-1431-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-17 2017 /pmc/articles/PMC5645916/ /pubmed/29041949 http://dx.doi.org/10.1186/s13075-017-1431-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tejera-Segura, Beatriz
López-Mejías, Raquel
Domínguez-Luis, María Jesús
de Vera-González, Antonia M.
González-Delgado, Alejandra
Ubilla, Begoña
Olmos, José M.
Hernández, José L.
González-Gay, Miguel A.
Ferraz-Amaro, Iván
Incretins in patients with rheumatoid arthritis
title Incretins in patients with rheumatoid arthritis
title_full Incretins in patients with rheumatoid arthritis
title_fullStr Incretins in patients with rheumatoid arthritis
title_full_unstemmed Incretins in patients with rheumatoid arthritis
title_short Incretins in patients with rheumatoid arthritis
title_sort incretins in patients with rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645916/
https://www.ncbi.nlm.nih.gov/pubmed/29041949
http://dx.doi.org/10.1186/s13075-017-1431-9
work_keys_str_mv AT tejerasegurabeatriz incretinsinpatientswithrheumatoidarthritis
AT lopezmejiasraquel incretinsinpatientswithrheumatoidarthritis
AT dominguezluismariajesus incretinsinpatientswithrheumatoidarthritis
AT deveragonzalezantoniam incretinsinpatientswithrheumatoidarthritis
AT gonzalezdelgadoalejandra incretinsinpatientswithrheumatoidarthritis
AT ubillabegona incretinsinpatientswithrheumatoidarthritis
AT olmosjosem incretinsinpatientswithrheumatoidarthritis
AT hernandezjosel incretinsinpatientswithrheumatoidarthritis
AT gonzalezgaymiguela incretinsinpatientswithrheumatoidarthritis
AT ferrazamaroivan incretinsinpatientswithrheumatoidarthritis